499 related articles for article (PubMed ID: 12421226)
1. Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays.
Galel SA; Strong DM; Tegtmeier GE; Holland PV; Kuramoto IK; Kemper M; Pietrelli L; Gallarda J
Transfusion; 2002 Nov; 42(11):1507-13. PubMed ID: 12421226
[TBL] [Abstract][Full Text] [Related]
2. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV.
Hitzler WE; Runkel S
Transfusion; 2001 Mar; 41(3):333-7. PubMed ID: 11274586
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of six blood donors highlights the complementary role and limitations of hepatitis C virus antibody and nucleic acid amplification tests.
Hyland C; Seed CR; Kiely P; Parker S; Cowley N; Bolton W
Vox Sang; 2003 Jul; 85(1):1-8. PubMed ID: 12823724
[TBL] [Abstract][Full Text] [Related]
4. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.
Stramer SL; Glynn SA; Kleinman SH; Strong DM; Caglioti S; Wright DJ; Dodd RY; Busch MP;
N Engl J Med; 2004 Aug; 351(8):760-8. PubMed ID: 15317889
[TBL] [Abstract][Full Text] [Related]
5. Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening.
Tobler LH; Stramer SL; Lee SR; Masecar BL; Peterson JE; Davis EA; Andrews WE; Brodsky JP; Kleinman SH; Phelps BH; Busch MP
Transfusion; 2003 Oct; 43(10):1452-9. PubMed ID: 14507279
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of 'window-phase' blood donations.
Lee SR; Peterson J; Niven P; Bahl C; Page E; DeLeys R; Giordano-Schmidt D; Baggett D; Green G
Vox Sang; 2001 Jan; 80(1):19-23. PubMed ID: 11339063
[TBL] [Abstract][Full Text] [Related]
7. Markers of hepatitis C infection among hemodialysis patients with acute and chronic infection: implications for infection control strategies in hemodialysis units.
Oliva JA; Ercilla G; Mallafre JM; Bruguera M; Carrió J; Pereira BJ
Int J Artif Organs; 1995 Feb; 18(2):73-7. PubMed ID: 7558399
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction.
Wang JT; Wang TH; Sheu JC; Tsai SJ; Hsieh YS; Lin DT; Wang CY; Chen DS
Arch Pathol Lab Med; 1993 Feb; 117(2):152-6. PubMed ID: 8381269
[TBL] [Abstract][Full Text] [Related]
9. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
El Ekiaby M; Moftah F; Goubran H; van Drimmelen H; LaPerche S; Kleinman S; Busch M; Lelie N
Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
[TBL] [Abstract][Full Text] [Related]
10. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening.
Jongerius JM; Sjerps M; Cuijpers HT; van Drimmelen HA; van der Poel CL; Reesink HW; Molijn MH; Peeters GA; Peeters TP; Lelie PN
Transfusion; 2002 Jun; 42(6):792-7. PubMed ID: 12147034
[TBL] [Abstract][Full Text] [Related]
11. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors.
Busch MP; Glynn SA; Stramer SL; Orland J; Murphy EL; Wright DJ; Kleinman S;
Transfusion; 2006 Mar; 46(3):469-75. PubMed ID: 16533292
[TBL] [Abstract][Full Text] [Related]
12. Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV antigen test in parallel with HCV RNA.
Alvarez M; Planelles D; Vila E; Montoro J; Franco E
Vox Sang; 2004 May; 86(4):266-7. PubMed ID: 15144533
[No Abstract] [Full Text] [Related]
13. Outcome of an optional HCV screening program for blood transfusion recipients in Ireland.
Davoren A; Dillon AD; Power JP; Donnellan J; Quinn JM; Willis JW; Lawlor EM; O'Riordan JM
Transfusion; 2002 Nov; 42(11):1501-6. PubMed ID: 12421225
[TBL] [Abstract][Full Text] [Related]
14. [Interpretation of hepatitis C virus serology: immunoblot and genome amplification].
Maniez-Montreuil M; Dubois F
Transfus Clin Biol; 2000 Jun; 7 Suppl 1():25s-30s. PubMed ID: 10919220
[TBL] [Abstract][Full Text] [Related]
15. Non-specific and specific anti-HCV results correlated to age, sex, transaminase, rhesus blood group and follow-up in blood donors.
Caspari G; Gerlich WH; Beyer J; Schmitt H
Arch Virol; 1997; 142(3):473-89. PubMed ID: 9349294
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: comparison with supplementary hepatitis C antibody assays.
Widell A; Månsson AS; Sundström G; Hansson BG; Nordenfelt E
J Med Virol; 1991 Dec; 35(4):253-8. PubMed ID: 1724983
[TBL] [Abstract][Full Text] [Related]
17. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays.
Kiely P; Kay D; Parker S; Piscitelli L
Transfusion; 2004 Mar; 44(3):349-58. PubMed ID: 14996191
[TBL] [Abstract][Full Text] [Related]
18. Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms.
Kleinman SH; Stramer SL; Brodsky JP; Caglioti S; Busch MP
Transfusion; 2006 May; 46(5):695-702. PubMed ID: 16686836
[TBL] [Abstract][Full Text] [Related]
19. [Significance of alanine aminotransferase screening in blood donors for risk reduction of hepatitis B and C transmission by haemotherapy].
Kusendová K; Gavorník P; Sabaka P; Sviteková K
Vnitr Lek; 2016 Jan; 62(1):9-16. PubMed ID: 26967232
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of indeterminate c22-3 reactivity in volunteer blood donors.
Tobler LH; Busch MP; Wilber J; Dinello R; Quan S; Polito A; Kochesky R; Bahl C; Nelles M; Lee SR
Transfusion; 1994 Feb; 34(2):130-4. PubMed ID: 8310482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
